LLY

1,070

-0.21%↓

JNJ

205.92

-0.04%↓

ABBV

224.87

-1%↓

UNH

326.18

-0.38%↓

AZN

91.36

+0.01%↑

LLY

1,070

-0.21%↓

JNJ

205.92

-0.04%↓

ABBV

224.87

-1%↓

UNH

326.18

-0.38%↓

AZN

91.36

+0.01%↑

LLY

1,070

-0.21%↓

JNJ

205.92

-0.04%↓

ABBV

224.87

-1%↓

UNH

326.18

-0.38%↓

AZN

91.36

+0.01%↑

LLY

1,070

-0.21%↓

JNJ

205.92

-0.04%↓

ABBV

224.87

-1%↓

UNH

326.18

-0.38%↓

AZN

91.36

+0.01%↑

LLY

1,070

-0.21%↓

JNJ

205.92

-0.04%↓

ABBV

224.87

-1%↓

UNH

326.18

-0.38%↓

AZN

91.36

+0.01%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

1.08 2.86

Buy Sell

Overview

Share price change

24h

Current

Min

1.05

Max

1.08

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+376.19% upside

Market Stats
By TradingEconomics
Market Cap	3.5M 129M
Previous open	-1.78
Previous close	1.08

News Sentiment

By Acuity

43%

57%

135 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 gru 2025, 17:29 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 gru 2025, 16:47 UTC

Major Market Movers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 gru 2025, 16:10 UTC

Acquisitions, Mergers, Takeovers

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

21 gru 2025, 23:51 UTC

Market Talk

Oil Rises Amid Growing U.S.-Venezuela Tensions -- Market Talk

21 gru 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 gru 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

21 gru 2025, 23:35 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

19 gru 2025, 22:33 UTC

Earnings

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 gru 2025, 22:19 UTC

Earnings

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 gru 2025, 21:48 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 21:44 UTC

Earnings

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 21:38 UTC

Earnings

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 gru 2025, 21:00 UTC

Market Talk

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 gru 2025, 20:23 UTC

Market Talk

Oil Futures End Down Week on Up Note -- Market Talk

19 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 gru 2025, 18:38 UTC

Market Talk

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 gru 2025, 18:00 UTC

Market Talk

Earnings

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 gru 2025, 17:41 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 gru 2025, 17:24 UTC

Market Talk

Earnings

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

19 gru 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

19 gru 2025, 16:29 UTC

Earnings

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 gru 2025, 16:20 UTC

Acquisitions, Mergers, Takeovers

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 gru 2025, 16:19 UTC

Acquisitions, Mergers, Takeovers

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 gru 2025, 16:18 UTC

Acquisitions, Mergers, Takeovers

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 gru 2025, 16:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19 gru 2025, 16:16 UTC

Market Talk

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 gru 2025, 16:05 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 16:04 UTC

Acquisitions, Mergers, Takeovers

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 gru 2025, 15:37 UTC

Market Talk

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

376.19% upside

12 Months Forecast

Average 5 USD 376.19%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

135 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.